Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Oncolytics Biotech Inc ONCY


Primary Symbol: T.ONC

Healthcare Biotechnology
Oncolytics Biotech Inc. is a biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to phase 3 licensure-enabling studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.


TSX:ONC - Post by User

Oncolytics Biotech Inc > Pelareorep + Paclitaxel = ADC/HER2 failed breast cancer
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(5714)
•••
Comment by Noteableon Aug 19, 2024 10:14am
142 Views
Post# 36185774

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE: Pelareorep + Paclitaxel = ADC/HER2 failed breast cancer

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE: Pelareorep + Paclitaxel = ADC/HER2 failed breast cancer

 

All FDA Approved ADC Therapies 
Enhertu Daiichi Sankyo NSCLC; gastric cancer; breast cancer 2019
Zynlonta ADC Therapeutics DLBCL 2021
Blenrep GlaxoSmithKline Multiple myeloma 2020
Tivdak Seagen Cervical cancer 2021
Trodelvy Gilead Sciences Bladder cancer; breast cancer 2020
Elahere ImmunoGen Ovarian cancer 2022
Polivy Roche DLBCL 2019
Padcev Astellas Bladder cancer 2019
Besponsa Pfizer ALL 2017
Kadcyla Roche Breast cancer 2013
Adcetris Seagen NHL; Hodgkin’s lymphoma 2011
Mylotarg Pfizer AML 2017 (reinstated)
Zevalin Aurobindo Pharma NHL, follicular lymphoma 2002

<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities